Search
Bezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Products: BEZAFIBRATO 200 MG, ZAFIBRAL TABLET 200 mgAsciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000] … [L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.
Products: AZEVAY 20 MG FİLM KAPLI TABLET , 60 ADET, AZEVAY 40 MG FİLM KAPLI TABLET , 60 ADETSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.
Products: TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADETSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.
Products: LUMAKRAS 120 MG FİLM KAPLI TABLET, 240 ADETTolbutamide
go.drugbank.com/drugs/DB01124ApprovedTolbutamide and its metabolites are excreted in urine (75-85%) and feces. … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.
Synonyms: N-n-Butyl-N'-tosylurea, N-(Sulfonyl-p-methylbenzene)-N'-N-butylureaCategories: Drugs Used in DiabetesMigalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigational[L47036,L47057,L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated … [L47036,L47057] As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and
Products: GALAFOLD 123 MG SERT KAPSÜL, 14 ADETSulthiame
go.drugbank.com/drugs/DB08329ApprovedProducts: Ospolot 50 mg Filmtabletten, Sultiam neuraxpharm 50 mg FilmtablettenAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.
Synonyms: 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrileProducts: ALECENSA (150 MG HARD CAPSULE), ALECENSA 150 MG SERT KAPSÜL, 224 ADETRilmenidine
go.drugbank.com/drugs/DB11738ApprovedWithdrawnRilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.
Products: HYPERIUM 1 MG TABLET, 30 ADET, Iterium 1 mg - Tablettenalpha-Fluoro-carboxymethyldethia coenzyme A complex
go.drugbank.com/drugs/DB03182ExperimentalSynonyms: alpha-Fluoro-carboxymethyldethia coenzyme A complex